As I’ve been saying for several years the question is do the hospitals/IDN’s care enough to buy SOZO?
Do they think lymphoedema prevention deserves a portion of their budget and resources?
How much money do they currently make from big pharma when a patient does get Lymphoedema (both from kick backs and other “support”)?
Is the return of integrating SOZO into their networks (with its additional time required to test, facilitate rebates etc worth the effort (even if we perceive that effort as “minimal”)?
If the last 12 months are anything to go on I would say no. Next couple of quarters are crucial - I would have lost a small fortune or we will begin a slow climb back. Now that would be the time to add to the position. Anything else is just money at the casino table.
Add to My Watchlist
What is My Watchlist?
